Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway

Life Sciences

Volumn 82, Issue 19-20, 2008, Pages 991-996

  Liu, Juan ^a   Shen, Qin ^a   Wu, Yang ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Angiotensinogen gene; Cardiac hypertrophy; Cardiotrophin 1; JAK STAT pathway; Simvastatin

Indexed keywords

CARDIOTROPHIN 1; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SIMVASTATIN; STAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CARDIOMEGALY; CELL SIZE; CYTOKINES; HEART VENTRICLES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JANUS KINASES; MALE; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; STAT TRANSCRIPTION FACTORS;

RATTUS;

EID: 42649089174     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.02.012     Document Type: Article

References (25)

1. Baker K.M., Chernin M.I., Schreiber T., Sanghi S., Haiderzaidi S., Booz G.W., Dostal D.E., and Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regulatory Peptides 120 1-3 (2004) 5-13
2. Barry S.P., Townsend P.A., Latchman D.S., and Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends in Molecular Medicine 13 2 (2007) 82-89
3. Booz G.W., Day J.N., and Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. Journal of Molecular and Cellular Cardiology 11 (2002) 1443-1453 Review
4. Bristow M.R., and Long C.S. Cardiotrophin-1 in heart failure. Circulation 106 12 (2002) 1430-1432
5. Dechend R., Fiebeler A., Park J.K., Muller D.N., Theuer J., Mervaala E., Bieringer M., Gulba D., Dietz R., Luft F.C., and Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104 5 (2001) 576-581
6. Fukuzawa J., Booz G.W., Hunt R.A., Shimizu N., Karoor V., Baker K.M., and Dostal D.E. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 35 6 (2000) 1191-1196
7. Guinamard R., and Bois P. Involvement of transient receptor potential proteins in cardiac hypertrophy. Biochimica et Biophysica Acta. Molecular Basis of Disease 1172 8 (2007) 885-894
8. Kaneta S., Satoh K., Kano S., Kanda M., and Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170 2 (2003) 237-243
9. Laufs U., Marra D., Node K., and Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). Journal of Biological Chemistry 274 31 (1999) 21926-21931
10. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X., and Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology 26 11 (1999) 903-908
11. Luo J.D., Xie F., Zhang W.W., Ma X.D., Guan J.X., and Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. British Journal of Pharmacology 132 1 (2001) 159-164
12. Morikawa-Futamatsu K., Adachi S., Maejima Y., Tamamori-Adachi M., Suzuki J., Kitajima S., Ito H., and Isobe M. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sciences 79 14 (2006) 1380-1390
13. Nozato T., Ito H., Tamamori M., Adachi S., Abe S., Marumo F., and Hiroe M. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Japanese Circulation Journal 64 8 (2000) 595-601
14. Oshima Y., Fujio Y., Nakanishi T., Itoh N., Yamamoto Y., Negoro S., Tanaka K., Kishimoto T., Kawase I., and Azuma J. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovascular Research 65 2 (2005) 428-435
15. Padmasekar M., Nandiqama R., Wartenberq M., Schluter K.D., and Sauer H. The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways. Cardiovascular Research 75 1 (2007) 118-128
16. Patel R., Naqueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., Quinones M.A., Zoqhbi W.A., Entman M.L., Roberts R., and Marian A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 3 (2001) 317-324
17. Rugale C., Delbosc S., Mimran A., and Jover B. Simvastatin reverses target organ damage and oxidative stress in angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. Journal of Cardiovascular Pharmacology 50 3 (2007) 293-298
18. Sarkar K., Sinha A.K., and Mehta J.L. The role of statins in endothelial dysfunction in hypertension. Current Opinion in Cardiology 21 4 (2006) 316-321
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 344 8934 (1994) 1383-1389
20. Takeishi Y., Goto K., and Kubota I. Role of diacylglycerol kinase in cellular regulatory processes: a new regulator for cardiomyocyte hypertrophy. Pharmacology and Therapeutics 115 3 (2007) 352-359
21. Undas A., Celinska-Lowenhoff M., Domagala T.B., Iwaniec T., Dropinski J., Lowenhoff T., and Szczeklik A. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thrombosis and Haemostasis 94 1 (2005) 193-199
22. Usui S., Yeh I., Tian B., and Sadoshima J. Global changes in gene expression during cardiac hypertrophy: a new direction of cardiac signaling research. Journal of Molecular and Cellular Cardiology 41 2 (2006) 219-222
23. Waters D.D. What the statin trials have taught us. The American Journal of Cardiology 98 1 (2006) 129-134
24. Wu L., Zhao L., Zheng Q., Shang F., Wang X., Wang L., and Lang B. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Molecular and Cellular Biochemistry 284 1-2 (2006) 65-71
25. Yamauchi-Takihara K., and Kishimoto T. Cytokines and their receptors in cardiovascular diseases-role of gp130 signaling pathway in cardiac myocyte growth and maintenance. International Journal of Experimental Pathology 81 1 (2000) 1-16